ZIOPHARM Oncology, Inc.
 (ZIOP)

- NASDAQ
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Dec. 4, 2015, 9:16 AM
    | Dec. 4, 2015, 9:16 AM
  • Nov. 2, 2015, 4:37 PM
    • ZIOPHARM Oncology (NASDAQ:ZIOP): Q3 EPS of -$0.14 misses by $0.02.
    • Revenue of $1.9M (+201.6% Y/Y) beats by $0.28M.
    • Shares -1.2%.
    | Nov. 2, 2015, 4:37 PM
  • Oct. 2, 2015, 9:12 AM
    | Oct. 2, 2015, 9:12 AM | 1 Comment
  • Sep. 18, 2015, 6:27 PM
    • Ziopharm (NASDAQ:ZIOP) has presented clinical and pre-clinical data for its Ad-RTS-IL-12 gene therapy candidate at a a cancer immunotherapy conference taking place in NYC from Sep. 16-19.
    • One presentation, titled "Demonstration of Systemic Antitumor Immunity via Intratumoral Regulated Expression of IL-12 in Advanced Breast Cancer and Melanoma Patients," is said to highlight "additional evidence of systemic immune activation with AD-RTS-hIL-12 and veledimex in advanced melanoma and breast cancer patients."
    • Another presentation, titled "Demonstration of Systemic Antitumor Immunity via Intratumoral Regulated Expression of IL-12 as a Gene Therapy Approach to Treatment of Cancer," is said to demonstrate "the anti-tumor effects and tolerability of Ad-RTS-mIL-12 in murine models of glioblastoma (brain cancer), colon cancer and melanoma."
    • Shares are up 1.5% after hours to $12.78, after rising 5.7% in regular trading.
    | Sep. 18, 2015, 6:27 PM | 12 Comments
  • Sep. 1, 2015, 9:13 AM
    | Sep. 1, 2015, 9:13 AM | 3 Comments
  • Aug. 25, 2015, 9:19 AM
    | Aug. 25, 2015, 9:19 AM | 7 Comments
  • Aug. 11, 2015, 9:16 AM
    | Aug. 11, 2015, 9:16 AM
  • Aug. 10, 2015, 4:37 PM
    • ZIOPHARM Oncology (NASDAQ:ZIOP): Q2 EPS of -$0.11 beats by $0.14.
    • Revenue of $0.27M (+35.0% Y/Y) misses by $1.33M.
    | Aug. 10, 2015, 4:37 PM
  • Jul. 24, 2015, 12:42 PM
    • The FDA designates Ziopharm Oncology's (ZIOP +4.2%) gene therapy candidate, Ad-RTS-hIL-12, an Orphan Drug for the treatment of malignant glioma, a brain tumor that originates in the brain or spine. Gliomas represent 30% of all brain and CNS tumors and 80% of brain tumors.
    • Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved. This is far in the distance, though. A Phase 1 trial evaluating Ad-RTS-hIL-12 in combination with veledimex is not yet recruiting patients.
    | Jul. 24, 2015, 12:42 PM | 4 Comments
  • Jun. 30, 2015, 8:24 AM
    | Jun. 30, 2015, 8:24 AM | 6 Comments
  • Jun. 22, 2015, 9:18 AM
    | Jun. 22, 2015, 9:18 AM | 2 Comments
  • Jun. 5, 2015, 8:48 AM
    • Interxon (NYSE:XON) sets the final ratio for its pro rata dividend distribution of all of its 17,830,305-share stake in Ziopharm (NASDAQ:ZIOP). XON stockholders of record on June 4 will receive 0.162203 shares of ZIOP per XON share and warrant holders will receive 0.16223 shares of ZIOP per XON share deliverable under the warrants. The stock will be delivered on or about June 12.
    • Intrexon announced the special dividend a month ago.
    | Jun. 5, 2015, 8:48 AM | 2 Comments
  • Jun. 2, 2015, 12:30 PM
    • According to Bloomberg, AstraZeneca (AZN +0.1%) CEO Pascal Soriot said that his firm would consider buying a company like Juno Therapeutics (JUNO +12.9%).
    • This isn't too surprising since oncology represents only 11% of AZN's business. CAR-Ts are all the rage in the cancer space. If their initial success can be validated in late-stage trials, they will command premium prices once approved, probably in the neighborhood of $500K per procedure. Acquiring one of the leaders would be a logical move for most members of Big Pharma or a number of larger biotechs. Juno's market cap is only $5.5B so it is not expensive if viewed on a long term basis.
    • Related tickers: (KITE +5.4%)(BLUE -0.5%)(BLCM +8.2%)(ZIOP +4%)(CLLS +4.4%)
    | Jun. 2, 2015, 12:30 PM | 15 Comments
  • Jun. 2, 2015, 10:16 AM
    • Ziopharm Oncology (ZIOP +0.7%) promotes EVP and Chief Legal Officer Caesar Belbel to Chief Operating Officer effective immediately. Mr. Belbel joined the firm in September 2011.
    | Jun. 2, 2015, 10:16 AM
  • May 8, 2015, 10:00 AM
    • ZIOPHARM Oncology (ZIOP +2.1%) Q1 results: Revenues: $0.3M (+50.0%); R&D Expense: $74.2M (+999%); SG&A: $4.3M (+26.5%); Operating Loss: ($78.2M) (-698.0%); Net Loss: ($78.2M) (-706.2%); Loss Per Share: ($0.69) (-590.0%); Quick Assets: $129.7M (+203.0%).
    • No guidance given.
    | May 8, 2015, 10:00 AM
  • May 7, 2015, 4:44 PM
    • ZIOPHARM Oncology (NASDAQ:ZIOP): Q1 EPS of -$0.10 beats by $0.03.
    • Revenue of $0.27M (+35.0% Y/Y) beats by $0.14M.
    | May 7, 2015, 4:44 PM | 10 Comments
Company Description
ZIOPHARM Oncology Inc is a biopharmaceutical company. The Company is engaged in the acquiring, developing and commercializing portfolio of cancer therapies that can address unmet medical needs through synthetic biology.
Sector: Healthcare
Industry: Biotechnology
Country: United States